

Data Sheet

Product Information

Catalog Number	BP16870
Product Name	XL041
Description	XL041 (BMS-852927) is an agonist of LXR β -selective.
In vitro	XL041 (BMS-852927) is an LXR β -selective agonist with 20% LXR α and 88% LXR β activity compared to a full pan agonist in transactivation assays. BMS-852927 has similar binding affinity to LXR α and LXR β (19 and 12 nM, respectively). XL041 is potent, with an EC ₅₀ =9 nM and 26% activity in an in vitro human whole-blood endogenous target gene activation assay (WBA).
In vivo	XL041 (BMS-852927) which has a very favorable profile at efficacious doses in cynomolgus monkeys and mice. In a separate study, XL041 inhibits the progression of atherosclerosis in a 12 week study in LDLR KO mice. XL041 pre-treatment of C57BL/6J mice for 7 days results in potent, dose-dependent stimulation of cholesterol efflux in this system; reaching a maximum in the 3 mg/kg/day dose group of 70% above vehicle in the initial efflux rate. Similar results are obtained in LDLR knockout (KO) mice. Importantly, the dose response for inhibition of atherosclerosis (0.1-3 mg/kg/day) is similar to the dose response for macrophage reverse cholesterol transport (RCT) stimulation (0.03-3 mg/kg/day), a major underlying mechanism through which LXR agonists affect the disease.
Synonyms	BMS-852927
CAS No.	1256918-39-4
Chemical Formula	C ₂₉ H ₂₈ Cl ₂ F ₂ N ₂ O ₄ S
Molecular Weight	609.51

Solubility	DMSO: 100 mg/mL (164.07 mM), Need ultrasonic
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<http://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022